Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX10 plus HLX07 in advanced head and neck cancer
CTR20200312Phase 2Suspended
- Sponsor
- HyBioPharma
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, pimurutamab in head and neck squamous cell carcinoma (HNSCC), sponsored by HyBioPharma. Started Jul 2020; status: suspended.
02
Drugs
serplulimabpimurutamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20200312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200312.